
What happened
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) director Laura Brege sold 14,167 shares after exercising options.
The filing says Brege still held 15,703 shares after the transactions, so the sale trimmed the position rather than closed it.
The shares were sold in two blocks at $94.05 and $94.74, far above the $16.71 exercise price, and the two blocks totaled about $1.33 million.
The derivative line ends at 0 after the exercise. The award was fully vested and carried a June 10, 2030 expiration, so it was ready to be turned into stock and sold.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Shares sold | 14,167 shares | SEC Form 4 | |
| Sale proceeds | $1.33 million | SEC Form 4 | |
| Shares held after sale | 15,703 shares | SEC Form 4 | |
| Weighted-average sale price, first transaction | $94.05 | SEC Form 4 | |
| Weighted-average sale price, second transaction | $94.74 | SEC Form 4 | |
| Exercise price | $16.71 | SEC Form 4 |
Read more: Mirum Pharmaceuticals (MIRM) company research
Why it matters
Those sold shares were 47.4% of the holding before the Nov. 11 trade. That is a large reduction for one director, even if the filing stops short of a complete departure.
OptimistFi has argued that Mirum's equity depends on a commercial franchise that keeps growing, retains payer access and supports a premium multiple.
This filing leaves that operating story unchanged, but it does show an insider reducing direct equity exposure after the award had already vested. It also shows the cash value of the sale without saying anything about the business itself.
The shares were sold in two transactions on the same day as the option exercise, and the filing shows the award's vesting date and expiration date. That makes the transaction look like executed compensation monetization rather than a new bet against the company.
The record covers one director and one day's transactions, so it establishes the size of the move but not a broader pattern. It also shows that the option exercise, not a new award, supplied the shares that were later sold.
Stock perps: every US stock that trades as a perpetual future, by leverage, live
What's next
Mirum's next quarterly report will be the next check on whether the commercial franchise is still converting revenue growth into operating cash and nearing operating profitability. A stronger report would support OptimistFi's view, while a weaker one would put the insider sale in a colder light.
More from OptimistFi
- MIRM stock: research and coverage of Mirum Pharmaceuticals
- Stock research on every company OptimistFi covers
From OptimistFi Perps
- Stock perps vs tokenized stocks: how US shares trade around the clock
- Weekend market prices: US stock indexes, gold and oil now
- Perps news: leveraged stocks, gold, FX and crypto on-chain
- Prop firms that fund crypto and stock perps traders: rules, prices and payouts
- Top perps movers today: stocks, commodities, FX and indices
Sources
- SEC Form 4 — Mirum director Laura Brege's option exercise and share sales.
Explore OptimistFi research on Mirum Pharmaceuticals, Inc.: https://optimistfi.com/stocks/MIRM
Browse Mirum Pharmaceuticals, Inc. company coverage and explore the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
Find available research on the Mirum Pharmaceuticals, Inc. company page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
